Charles Schwab Investment Management Inc Vaxcyte, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,341,773 shares of PCVX stock, worth $99.8 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,341,773
Previous 1,295,837
3.54%
Holding current value
$99.8 Million
Previous $148 Million
25.76%
% of portfolio
0.02%
Previous 0.03%
Shares
18 transactions
Others Institutions Holding PCVX
# of Institutions
350Shares Held
130MCall Options Held
539KPut Options Held
253K-
Vanguard Group Inc Valley Forge, PA12MShares$890 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$786 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$739 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$646 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$462 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.41B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...